The IPO Buzz: Jyong Biotech (MENS) Prices IPO at $7.50 – Low End – & Soars on NASDAQ
Jyong Biotech Ltd. (MENS), a Taiwan-based biotech developing drugs to treat benign prostate hyperplasia and to prevent prostate cancer, priced its IPO at $7.50 – the low end of its range – and sold 2.7 million shares – the number of shares in the prospectus – to raise $20.0 million on Monday night, June 16, 2025. Jyong Biotech’s stock doubled its IPO price - scoring a moonshot when it op..
Read more June 17, 2025IPO Calendar
| Company | Symbol proposed | Shares (Millions) | Est. $ Volume | Expected to Trade | SCOOP Rating | Rating Change |
|---|---|---|---|---|---|---|
| Jyong Biotech Ltd. (Revived IPO) | MENS | 2.7 | $ 20.0 mil | 6/17/2025 Priced | S/O | S/O |
| Axiom Intelligence Acquisition Corp. I | AXINU | 17.5 | $ 175.0 mil | 6/18/2025 Priced | S/O | S/O |
| Caris Life Sciences, Inc. | CAI | 23.5 | $ 458.8 mil | 6/18/2025 Wednesday | S/O | S/O |
Last 100 IPOs - June 17, 2025
| Number of IPOs priced : | 100 |
| Number Up: | 58 |
| Number Down: | 39 |
| Number Unchanged: | 3 |
| Percentage Change From Issue Price: | 26.41% |
| Percentage Change for The Nasdaq Composite | 35.22% |
2025 IPO Scorecard - June 17, 2025
| Number of IPOs priced (Excluding 55 units) : | 106 |
| Number Up: | 60 |
| Number Down: | 43 |
| Number Unchanged: | 3 |
| Total Return From Issue Price: | 24.44% |
| The Nasdaq Composite Index YTD % Change | 35.22% |